ProCE Banner Activity

Switching ART in Patients With Prior Resistance

Clinical Thought

Here’s my take on how to optimize the switching of antiretroviral therapy in patients with virologic suppression and a history of antiretroviral resistance.

Released: October 17, 2022

Expiration: October 16, 2023

No longer available for credit.

Share

Faculty

Paul E. Sax

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Bruce A. and Robert L. Beal Distinguished Chair in Infectious Diseases
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Bruce A. and Robert L. Beal Distinguished Chair in Infectious Diseases
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen; researcher: Gilead Sciences, GlaxoSmithKline/ViiV Healthcare.